{"ticker": {"uuid": "c530580c-cf29-4580-a1ff-a5cc54bf23e7", "symbol": "IKT", "name": "Inhibikase Therapeutics\u00a0Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Inhibikase Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition", "summary": "This article is a preliminary proxy statement (PRE 14A) filed by Inhibikase Therapeutics. The document pertains to a merger or acquisition, indicating that the company is involved in a corporate transaction that requires shareholder approval or notification. The specific details ", "url": "https://www.moomoo.com/news/notice/306979807/inhibikase-therapeutics-pre-14a-preliminary-proxy-statements-relating-to-merger", "source_name": "Moomoo", "published_at": "2026-07-21T08:41:10", "published_display": "21 Jul 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Frontier tech research, news & data", "summary": "This article provides an inventory turnover analysis for Inhibikase Therapeutics, Inc. (IKT), drawing data from SEC EDGAR filings. It presents both annual and quarterly inventory turnover figures, noting that the company's inventory turnover was \"\u2014\" for all listed periods, indica", "url": "https://mlq.ai/companies/inhibikase-therapeutics-inc/inventory-turnover/", "source_name": "MLQ.ai", "published_at": "2026-07-20T08:41:10", "published_display": "20 Jul 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RA Capital Management files initial beneficial ownership statement in Inhibikase Therapeutics", "summary": "RA Capital Management has filed an initial beneficial ownership statement (Form 3) for Inhibikase Therapeutics, declaring indirect ownership of 25 million common shares. This filing indicates RA Capital owns 10% of Inhibikase Therapeutics. The event date for the ownership was Jul", "url": "https://www.bitget.com/amp/news/detail/12560605515876", "source_name": "Bitget", "published_at": "2026-07-18T20:11:14", "published_display": "18 Jul 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibikase Therapeutics (NASDAQ:IKT) Rating Lowered to Strong Sell at Wall Street Zen", "summary": "Wall Street Zen has downgraded Inhibikase Therapeutics (NASDAQ:IKT) from a \"sell\" to a \"strong sell\" rating. Despite this downgrade, other analysts maintain a more positive outlook, with a consensus \"Buy\" rating and an average price target of $5.40. The company, a clinical-stage ", "url": "https://www.marketbeat.com/instant-alerts/inhibikase-therapeutics-nasdaqikt-rating-lowered-to-strong-sell-at-wall-street-zen-2026-07-18/", "source_name": "MarketBeat", "published_at": "2026-07-18T05:39:34", "published_display": "18 Jul 2026 05:39", "sentiment": "negative", "sentiment_pct": 33, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RA Capital discloses 25M-share stake in Inhibikase Therapeutics (IKT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxPVzlyNU1aZmtOcGh4anVTb09zYUl4VkQ3WGpDOUlMZkMyRWg3SmlHOTA2VjBaNEhRS0lvQmMzQXo4NHVXRXJqTFg2eERqM09FVVI2djN6Mmd5UlJ2cW50d2FjRFNsM2JEX0lTR2hCRGdCOFFPZzVVU2xDdV9HOC1PSWJGR3F3R3k2c0Rkb3J1ZURfdVhwV3BkRjEydU5nMmtVSGd5MjVFa2szUFM3TW9OU2ktWFEtVUFJVFdNRFZBM1JlT2tuci13cklR?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-17T21:55:07+00:00", "published_display": "17 Jul 2026 21:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RA Capital (NASDAQ: IKT) reports 25M-share, 15.9% stake in Inhibikase", "summary": "RA Capital, through its Healthcare Fund, has reported a 15.9% stake in Inhibikase Therapeutics (IKT), holding 25 million shares. This ownership arose from an at-the-market offering on July 10, 2026, and the percentage is calculated based on an updated share count including these ", "url": "https://www.stocktitan.net/sec-filings/IKT/schedule-13g-inhibikase-therapeutics-inc-passive-investment-disclosur-4f5040a2c57c.html", "source_name": "Stock Titan", "published_at": "2026-07-17T21:39:34", "published_display": "17 Jul 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility", "summary": "Inhibikase Therapeutics, Inc. announced the sale of 25 million shares of its common stock to RA Capital Management through its at-the-market (ATM) facility for gross proceeds of $50 million. This capital, combined with existing reserves, is expected to fund operations through the", "url": "https://www.sahmcapital.com/news/content/inhibikase-therapeutics-announces-sale-of-50-million-of-shares-through-its-at-the-market-atm-facility-2026-07-14", "source_name": "Sahm", "published_at": "2026-07-15T20:39:25", "published_display": "15 Jul 2026 20:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibikase Therapeutics Shares Rise on $50M At\u2010the\u2010Market Share Sale", "summary": "Inhibikase Therapeutics recently announced a $50 million \"At-the-Market\" (ATM) share sale agreement with A.G.P./Alliance Global Partners. This agreement allows the company to sell common stock periodically, aiming to raise capital for general corporate purposes, including R&D and", "url": "https://www.moomoo.com/news/post/72947877/inhibikase-therapeutics-shares-rise-on-50m-at-the-market-share", "source_name": "Moomoo", "published_at": "2026-07-15T07:10:39", "published_display": "15 Jul 2026 07:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Average Rating of \"Buy\" by Brokerages", "summary": "Nine brokerages have given Inhibikase Therapeutics (NASDAQ:IKT) an average \"Buy\" rating, with a consensus 12-month price target of $5.40. The ratings include one \"sell,\" one \"hold,\" three \"buy,\" and four \"strong buy\" recommendations. Recent analyst activity includes upgrades, new", "url": "https://www.marketbeat.com/instant-alerts/inhibikase-therapeutics-inc-nasdaqikt-given-average-rating-of-buy-by-brokerages-2026-07-15/", "source_name": "MarketBeat", "published_at": "2026-07-15T06:12:57", "published_display": "15 Jul 2026 06:12", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibikase raises $50 million through stock sale to RA Capital", "summary": "Inhibikase Therapeutics, Inc. (NASDAQ:IKT) has raised $50 million by selling 25 million shares of common stock to RA Capital Management. This financing significantly increases the company's capital, validating its clinical-stage pipeline. The funds, combined with existing cash, a", "url": "https://www.investing.com/news/company-news/inhibikase-raises-50-million-through-stock-sale-to-ra-capital-93CH-4790682", "source_name": "Investing.com", "published_at": "2026-07-14T14:18:29", "published_display": "14 Jul 2026 14:18", "sentiment": "positive", "sentiment_pct": 73, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibikase Therapeutics (NASDAQ:IKT) Rating Increased to Strong-Buy at LADENBURG THALM/SH SH", "summary": "LADENBURG THALM/SH SH has upgraded Inhibikase Therapeutics (NASDAQ:IKT) to a \"strong-buy\" rating. This upgrade is part of a generally positive analyst outlook, with Oppenheimer initiating coverage with an outperform rating and a $5.00 price target. The company currently holds an ", "url": "https://www.marketbeat.com/instant-alerts/inhibikase-therapeutics-nasdaqikt-rating-increased-to-strong-buy-at-ladenburg-thalmsh-sh-2026-07-14/", "source_name": "MarketBeat", "published_at": "2026-07-14T12:12:55", "published_display": "14 Jul 2026 12:12", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibikase raises $50 million through stock sale to RA Capital By Investing.com", "summary": "Inhibikase Therapeutics, Inc. (NASDAQ:IKT) has successfully raised $50 million by selling 25 million shares of common stock to RA Capital Management. This financing significantly boosts the clinical-stage company's financial position, supporting its operations through a key data ", "url": "https://ca.investing.com/news/stock-market-news/inhibikase-raises-50-million-through-stock-sale-to-ra-capital-93CH-4733065", "source_name": "Investing.com Canada", "published_at": "2026-07-14T12:12:55", "published_display": "14 Jul 2026 12:12", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibikase Therapeutics (Nasdaq: IKT) sells 25M shares for $50M cash", "summary": "Inhibikase Therapeutics (Nasdaq: IKT) announced the sale of 25 million shares of common stock to RA Capital Management through an at-the-market facility, generating $50 million in gross proceeds. This capital, combined with existing cash, is expected to fund operations through th", "url": "https://www.stocktitan.net/sec-filings/IKT/8-k-inhibikase-therapeutics-inc-reports-material-event-cdb3f95356e3.html", "source_name": "Stock Titan", "published_at": "2026-07-14T12:12:55", "published_display": "14 Jul 2026 12:12", "sentiment": "positive", "sentiment_pct": 65, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibikase Therapeutics Sells $50M of Stock to RA Capital via ATM Facility", "summary": "Inhibikase Therapeutics (IKT) sold 25 million shares for $50 million to RA Capital through an at-the-market (ATM) facility. These proceeds, combined with existing cash, are expected to fund operations through the topline Part B readout of the Phase 3 IMPROVE-PAH study. The financ", "url": "https://www.tradingview.com/news/tradingview:c99b081d17085:0-inhibikase-therapeutics-sells-50m-of-stock-to-ra-capital-via-atm-facility/", "source_name": "TradingView", "published_at": "2026-07-14T12:12:55", "published_display": "14 Jul 2026 12:12", "sentiment": "positive", "sentiment_pct": 59, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibikase Therapeutics (NASDAQ:IKT) Shares Down 3.9% - Here's What Happened", "summary": "Inhibikase Therapeutics (NASDAQ:IKT) shares dropped 3.9% during midday trading on Monday, with the stock closing at $1.96 after reaching a low of $1.95. Trading volume was significantly below average, and the company recently reported earnings that matched Wall Street expectation", "url": "https://www.marketbeat.com/instant-alerts/inhibikase-therapeutics-nasdaqikt-shares-down-39-heres-what-happened-2026-07-14/", "source_name": "MarketBeat", "published_at": "2026-07-14T06:06:48", "published_display": "14 Jul 2026 06:06", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Inhibikase Therapeutics announced the grant of non-qualified stock options to seven new non-executive employees. These grants, totaling 981,243 shares, were made under the company's 2026 Inducement Equity Plan and approved by the Compensation Committee in accordance with Nasdaq L", "url": "https://www.manilatimes.net/2026/07/03/tmt-newswire/globenewswire/inhibikase-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4/2377794", "source_name": "The Manila Times", "published_at": "2026-07-03T02:40:16", "published_display": "03 Jul 2026 02:40", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibikase awards stock options to 7 new hires under inducement plan", "summary": "Inhibikase Therapeutics (Nasdaq: IKT) granted non-qualified stock options for up to 981,243 shares to seven new non-executive employees under its 2026 Inducement Equity Plan, effective June 30, 2026. These options have an exercise price of $2.03 per share, a ten-year term, and a ", "url": "https://www.stocktitan.net/news/IKT/inhibikase-therapeutics-announces-inducement-grants-under-nasdaq-s0e6vygsew3p.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:14:22", "published_display": "02 Jul 2026 20:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Inhibikase (NASDAQ: IKT) receives 155K stock options grant", "summary": "Inhibikase Therapeutics, Inc. director Amit Munshi was granted stock options to acquire 155,000 shares of common stock at an exercise price of $1.91 per share. These options are compensation-related and vest on the earlier of June 26, 2027, or the day before the next annual stock", "url": "https://www.stocktitan.net/sec-filings/IKT/form-4-inhibikase-therapeutics-inc-insider-trading-activity-d7f4b88ba8fa.html", "source_name": "Stock Titan", "published_at": "2026-07-01T01:39:17", "published_display": "01 Jul 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibikase (IKT) director awarded 155,000 stock options at $1.91 exercise price", "summary": "Inhibikase Therapeutics, Inc. (IKT) director Arvind Kush was granted 155,000 stock options with an exercise price of $1.91 per share. These options, awarded at no cost, will vest on the earlier of June 26, 2027, or the day before the company's next annual meeting, contingent on h", "url": "https://www.stocktitan.net/sec-filings/IKT/form-4-inhibikase-therapeutics-inc-insider-trading-activity-04dae062185c.html", "source_name": "Stock Titan", "published_at": "2026-07-01T01:39:17", "published_display": "01 Jul 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibikase (IKT) director receives 155,000 stock options at $1.91 strike", "summary": "Inhibikase Therapeutics director Roberto Bellini was granted 155,000 stock options with an exercise price of $1.91 per share, expiring on June 26, 2036. The options will vest on the earlier of June 26, 2027, or the day before the next annual stockholders' meeting, provided he rem", "url": "https://www.stocktitan.net/sec-filings/IKT/form-4-inhibikase-therapeutics-inc-insider-trading-activity-8d53a3377fe3.html", "source_name": "Stock Titan", "published_at": "2026-06-30T19:39:17", "published_display": "30 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibikase (IKT) director Dennis Berman granted options for 155,000 shares", "summary": "Inhibikase Therapeutics director Dennis N. Berman has been granted stock options for 155,000 shares of common stock, with an exercise price of $1.91 per share and an expiration date of June 26, 2036. The options will vest on the earlier of June 26, 2027, or the day before the nex", "url": "https://www.stocktitan.net/sec-filings/IKT/form-4-inhibikase-therapeutics-inc-insider-trading-activity-2aae71f2803e.html", "source_name": "Stock Titan", "published_at": "2026-06-30T19:39:17", "published_display": "30 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibikase Therapeutics (IKT) director granted 155,000 options at $1.91 strike", "summary": "Inhibikase Therapeutics (IKT) director Vincent Aurentz was granted 155,000 stock options with an exercise price of $1.91 per share, expiring on June 26, 2036. These options will vest on the earlier of June 26, 2027, or the day before the next annual stockholder meeting, contingen", "url": "https://www.stocktitan.net/sec-filings/IKT/form-4-inhibikase-therapeutics-inc-insider-trading-activity-1381fedc12ed.html", "source_name": "Stock Titan", "published_at": "2026-06-30T19:39:17", "published_display": "30 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibikase (IKT) director receives 155,000 stock options at $1.91 strike price", "summary": "Inhibikase Therapeutics, Inc. director David Canner was granted 155,000 stock options with an exercise price of $1.91 per share, expiring on June 26, 2036. The options will vest upon his continued board service, on the earlier of June 26, 2027, or the day before the next annual s", "url": "https://www.stocktitan.net/sec-filings/IKT/form-4-inhibikase-therapeutics-inc-insider-trading-activity-95296694843f.html", "source_name": "Stock Titan", "published_at": "2026-06-30T19:39:17", "published_display": "30 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibikase (NASDAQ: IKT) investors back 3M-share plan boost and officer protections", "summary": "Inhibikase Therapeutics, Inc. stockholders approved all six management proposals at its 2026 annual meeting, including an amendment to its 2020 Equity Incentive Plan to increase shares reserved for issuance by 3,000,000 common shares. They also approved a certificate of amendment", "url": "https://www.stocktitan.net/sec-filings/IKT/8-k-inhibikase-therapeutics-inc-reports-material-event-f3f643a4b7ed.html", "source_name": "Stock Titan", "published_at": "2026-06-29T09:42:11", "published_display": "29 Jun 2026 09:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Inhibikase Therapeutics, Inc. \u2013 NASDAQ:IKT", "summary": "This article focuses on the \"Price to book forward\" metric for Inhibikase Therapeutics, Inc. (NASDAQ: IKT), indicating financial data for the company. It appears to be a financial data snippet from a larger platform rather than a detailed news analysis. The content is brief and p", "url": "https://www.tradingview.com/symbols/NASDAQ-IKT/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T03:39:38", "published_display": "29 Jun 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Inhibikase Therapeutics, Inc. \u2013 NASDAQ:IKT", "summary": "This article provides financial data for Inhibikase Therapeutics, Inc. (NASDAQ: IKT), focusing on its enterprise value to EBITDA forward metric. The information is presented by TradingView, a platform offering market data and financial analysis tools. It highlights key financial ", "url": "https://www.tradingview.com/symbols/NASDAQ-IKT/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T13:40:12", "published_display": "28 Jun 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oppenheimer Initiates Inhibikase Therapeutics at Outperform", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/oppenheimer-initiates-inhibikase-therapeutics-outperform-105359668.html", "source_name": "MT Newswires", "published_at": "2026-06-10T10:53:59+00:00", "published_display": "10 Jun 2026 10:53", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity", "summary": "", "url": "https://finance.yahoo.com/news/inhibikase-therapeutics-announces-first-quarter-200100211.html", "source_name": "GlobeNewswire", "published_at": "2026-05-12T20:01:00+00:00", "published_display": "12 May 2026 20:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look At Inhibikase Therapeutics (IKT) Valuation After New FDA Designations And Phase 2a Trial Progress", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-27T08:00:00+00:00", "published_display": "27 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibikase Therapeutics Announces Pricing of $110 Million", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "GlobeNewswire", "published_at": "2024-10-09T07:00:00+00:00", "published_display": "09 Oct 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibikase Therapeutics (IKT) Stock Price, News & Analysis $IKT", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWEFVX3lxTE13SXBYWkFQenVaU2FEYUN0R0JnRlV4MkFYXzhOcFc5SlhXMC1EMFM2YlV2MXItbzFJdmFCbUVlOVJsMVhKTmtWMDdRT0s2R0phVEd2dkFXZUw?oc=5", "source_name": "MarketBeat", "published_at": "2021-08-06T15:01:16+00:00", "published_display": "06 Aug 2021 15:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Inhibikase Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition", "summary": "This article is a preliminary proxy statement (PRE 14A) filed by Inhibikase Therapeutics. The document pertains to a merger or acquisition, indicating that the company is involved in a corporate transaction that requires shareholder approval or notification. The specific details ", "url": "https://www.moomoo.com/news/notice/306979807/inhibikase-therapeutics-pre-14a-preliminary-proxy-statements-relating-to-merger", "source_name": "Moomoo", "published_at": "2026-07-21T08:41:10", "published_display": "21 Jul 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Frontier tech research, news & data", "summary": "This article provides an inventory turnover analysis for Inhibikase Therapeutics, Inc. (IKT), drawing data from SEC EDGAR filings. It presents both annual and quarterly inventory turnover figures, noting that the company's inventory turnover was \"\u2014\" for all listed periods, indica", "url": "https://mlq.ai/companies/inhibikase-therapeutics-inc/inventory-turnover/", "source_name": "MLQ.ai", "published_at": "2026-07-20T08:41:10", "published_display": "20 Jul 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RA Capital Management files initial beneficial ownership statement in Inhibikase Therapeutics", "summary": "RA Capital Management has filed an initial beneficial ownership statement (Form 3) for Inhibikase Therapeutics, declaring indirect ownership of 25 million common shares. This filing indicates RA Capital owns 10% of Inhibikase Therapeutics. The event date for the ownership was Jul", "url": "https://www.bitget.com/amp/news/detail/12560605515876", "source_name": "Bitget", "published_at": "2026-07-18T20:11:14", "published_display": "18 Jul 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibikase Therapeutics (NASDAQ:IKT) Rating Lowered to Strong Sell at Wall Street Zen", "summary": "Wall Street Zen has downgraded Inhibikase Therapeutics (NASDAQ:IKT) from a \"sell\" to a \"strong sell\" rating. Despite this downgrade, other analysts maintain a more positive outlook, with a consensus \"Buy\" rating and an average price target of $5.40. The company, a clinical-stage ", "url": "https://www.marketbeat.com/instant-alerts/inhibikase-therapeutics-nasdaqikt-rating-lowered-to-strong-sell-at-wall-street-zen-2026-07-18/", "source_name": "MarketBeat", "published_at": "2026-07-18T05:39:34", "published_display": "18 Jul 2026 05:39", "sentiment": "negative", "sentiment_pct": 33, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RA Capital discloses 25M-share stake in Inhibikase Therapeutics (IKT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxPVzlyNU1aZmtOcGh4anVTb09zYUl4VkQ3WGpDOUlMZkMyRWg3SmlHOTA2VjBaNEhRS0lvQmMzQXo4NHVXRXJqTFg2eERqM09FVVI2djN6Mmd5UlJ2cW50d2FjRFNsM2JEX0lTR2hCRGdCOFFPZzVVU2xDdV9HOC1PSWJGR3F3R3k2c0Rkb3J1ZURfdVhwV3BkRjEydU5nMmtVSGd5MjVFa2szUFM3TW9OU2ktWFEtVUFJVFdNRFZBM1JlT2tuci13cklR?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-17T21:55:07+00:00", "published_display": "17 Jul 2026 21:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RA Capital (NASDAQ: IKT) reports 25M-share, 15.9% stake in Inhibikase", "summary": "RA Capital, through its Healthcare Fund, has reported a 15.9% stake in Inhibikase Therapeutics (IKT), holding 25 million shares. This ownership arose from an at-the-market offering on July 10, 2026, and the percentage is calculated based on an updated share count including these ", "url": "https://www.stocktitan.net/sec-filings/IKT/schedule-13g-inhibikase-therapeutics-inc-passive-investment-disclosur-4f5040a2c57c.html", "source_name": "Stock Titan", "published_at": "2026-07-17T21:39:34", "published_display": "17 Jul 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility", "summary": "Inhibikase Therapeutics, Inc. announced the sale of 25 million shares of its common stock to RA Capital Management through its at-the-market (ATM) facility for gross proceeds of $50 million. This capital, combined with existing reserves, is expected to fund operations through the", "url": "https://www.sahmcapital.com/news/content/inhibikase-therapeutics-announces-sale-of-50-million-of-shares-through-its-at-the-market-atm-facility-2026-07-14", "source_name": "Sahm", "published_at": "2026-07-15T20:39:25", "published_display": "15 Jul 2026 20:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibikase Therapeutics Shares Rise on $50M At\u2010the\u2010Market Share Sale", "summary": "Inhibikase Therapeutics recently announced a $50 million \"At-the-Market\" (ATM) share sale agreement with A.G.P./Alliance Global Partners. This agreement allows the company to sell common stock periodically, aiming to raise capital for general corporate purposes, including R&D and", "url": "https://www.moomoo.com/news/post/72947877/inhibikase-therapeutics-shares-rise-on-50m-at-the-market-share", "source_name": "Moomoo", "published_at": "2026-07-15T07:10:39", "published_display": "15 Jul 2026 07:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Average Rating of \"Buy\" by Brokerages", "summary": "Nine brokerages have given Inhibikase Therapeutics (NASDAQ:IKT) an average \"Buy\" rating, with a consensus 12-month price target of $5.40. The ratings include one \"sell,\" one \"hold,\" three \"buy,\" and four \"strong buy\" recommendations. Recent analyst activity includes upgrades, new", "url": "https://www.marketbeat.com/instant-alerts/inhibikase-therapeutics-inc-nasdaqikt-given-average-rating-of-buy-by-brokerages-2026-07-15/", "source_name": "MarketBeat", "published_at": "2026-07-15T06:12:57", "published_display": "15 Jul 2026 06:12", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibikase raises $50 million through stock sale to RA Capital", "summary": "Inhibikase Therapeutics, Inc. (NASDAQ:IKT) has raised $50 million by selling 25 million shares of common stock to RA Capital Management. This financing significantly increases the company's capital, validating its clinical-stage pipeline. The funds, combined with existing cash, a", "url": "https://www.investing.com/news/company-news/inhibikase-raises-50-million-through-stock-sale-to-ra-capital-93CH-4790682", "source_name": "Investing.com", "published_at": "2026-07-14T14:18:29", "published_display": "14 Jul 2026 14:18", "sentiment": "positive", "sentiment_pct": 73, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibikase Therapeutics (NASDAQ:IKT) Rating Increased to Strong-Buy at LADENBURG THALM/SH SH", "summary": "LADENBURG THALM/SH SH has upgraded Inhibikase Therapeutics (NASDAQ:IKT) to a \"strong-buy\" rating. This upgrade is part of a generally positive analyst outlook, with Oppenheimer initiating coverage with an outperform rating and a $5.00 price target. The company currently holds an ", "url": "https://www.marketbeat.com/instant-alerts/inhibikase-therapeutics-nasdaqikt-rating-increased-to-strong-buy-at-ladenburg-thalmsh-sh-2026-07-14/", "source_name": "MarketBeat", "published_at": "2026-07-14T12:12:55", "published_display": "14 Jul 2026 12:12", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibikase raises $50 million through stock sale to RA Capital By Investing.com", "summary": "Inhibikase Therapeutics, Inc. (NASDAQ:IKT) has successfully raised $50 million by selling 25 million shares of common stock to RA Capital Management. This financing significantly boosts the clinical-stage company's financial position, supporting its operations through a key data ", "url": "https://ca.investing.com/news/stock-market-news/inhibikase-raises-50-million-through-stock-sale-to-ra-capital-93CH-4733065", "source_name": "Investing.com Canada", "published_at": "2026-07-14T12:12:55", "published_display": "14 Jul 2026 12:12", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibikase Therapeutics (Nasdaq: IKT) sells 25M shares for $50M cash", "summary": "Inhibikase Therapeutics (Nasdaq: IKT) announced the sale of 25 million shares of common stock to RA Capital Management through an at-the-market facility, generating $50 million in gross proceeds. This capital, combined with existing cash, is expected to fund operations through th", "url": "https://www.stocktitan.net/sec-filings/IKT/8-k-inhibikase-therapeutics-inc-reports-material-event-cdb3f95356e3.html", "source_name": "Stock Titan", "published_at": "2026-07-14T12:12:55", "published_display": "14 Jul 2026 12:12", "sentiment": "positive", "sentiment_pct": 65, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibikase Therapeutics Sells $50M of Stock to RA Capital via ATM Facility", "summary": "Inhibikase Therapeutics (IKT) sold 25 million shares for $50 million to RA Capital through an at-the-market (ATM) facility. These proceeds, combined with existing cash, are expected to fund operations through the topline Part B readout of the Phase 3 IMPROVE-PAH study. The financ", "url": "https://www.tradingview.com/news/tradingview:c99b081d17085:0-inhibikase-therapeutics-sells-50m-of-stock-to-ra-capital-via-atm-facility/", "source_name": "TradingView", "published_at": "2026-07-14T12:12:55", "published_display": "14 Jul 2026 12:12", "sentiment": "positive", "sentiment_pct": 59, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibikase Therapeutics (NASDAQ:IKT) Shares Down 3.9% - Here's What Happened", "summary": "Inhibikase Therapeutics (NASDAQ:IKT) shares dropped 3.9% during midday trading on Monday, with the stock closing at $1.96 after reaching a low of $1.95. Trading volume was significantly below average, and the company recently reported earnings that matched Wall Street expectation", "url": "https://www.marketbeat.com/instant-alerts/inhibikase-therapeutics-nasdaqikt-shares-down-39-heres-what-happened-2026-07-14/", "source_name": "MarketBeat", "published_at": "2026-07-14T06:06:48", "published_display": "14 Jul 2026 06:06", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Inhibikase Therapeutics announced the grant of non-qualified stock options to seven new non-executive employees. These grants, totaling 981,243 shares, were made under the company's 2026 Inducement Equity Plan and approved by the Compensation Committee in accordance with Nasdaq L", "url": "https://www.manilatimes.net/2026/07/03/tmt-newswire/globenewswire/inhibikase-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4/2377794", "source_name": "The Manila Times", "published_at": "2026-07-03T02:40:16", "published_display": "03 Jul 2026 02:40", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibikase awards stock options to 7 new hires under inducement plan", "summary": "Inhibikase Therapeutics (Nasdaq: IKT) granted non-qualified stock options for up to 981,243 shares to seven new non-executive employees under its 2026 Inducement Equity Plan, effective June 30, 2026. These options have an exercise price of $2.03 per share, a ten-year term, and a ", "url": "https://www.stocktitan.net/news/IKT/inhibikase-therapeutics-announces-inducement-grants-under-nasdaq-s0e6vygsew3p.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:14:22", "published_display": "02 Jul 2026 20:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Inhibikase (NASDAQ: IKT) receives 155K stock options grant", "summary": "Inhibikase Therapeutics, Inc. director Amit Munshi was granted stock options to acquire 155,000 shares of common stock at an exercise price of $1.91 per share. These options are compensation-related and vest on the earlier of June 26, 2027, or the day before the next annual stock", "url": "https://www.stocktitan.net/sec-filings/IKT/form-4-inhibikase-therapeutics-inc-insider-trading-activity-d7f4b88ba8fa.html", "source_name": "Stock Titan", "published_at": "2026-07-01T01:39:17", "published_display": "01 Jul 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibikase (IKT) director awarded 155,000 stock options at $1.91 exercise price", "summary": "Inhibikase Therapeutics, Inc. (IKT) director Arvind Kush was granted 155,000 stock options with an exercise price of $1.91 per share. These options, awarded at no cost, will vest on the earlier of June 26, 2027, or the day before the company's next annual meeting, contingent on h", "url": "https://www.stocktitan.net/sec-filings/IKT/form-4-inhibikase-therapeutics-inc-insider-trading-activity-04dae062185c.html", "source_name": "Stock Titan", "published_at": "2026-07-01T01:39:17", "published_display": "01 Jul 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibikase (IKT) director receives 155,000 stock options at $1.91 strike", "summary": "Inhibikase Therapeutics director Roberto Bellini was granted 155,000 stock options with an exercise price of $1.91 per share, expiring on June 26, 2036. The options will vest on the earlier of June 26, 2027, or the day before the next annual stockholders' meeting, provided he rem", "url": "https://www.stocktitan.net/sec-filings/IKT/form-4-inhibikase-therapeutics-inc-insider-trading-activity-8d53a3377fe3.html", "source_name": "Stock Titan", "published_at": "2026-06-30T19:39:17", "published_display": "30 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibikase (IKT) director Dennis Berman granted options for 155,000 shares", "summary": "Inhibikase Therapeutics director Dennis N. Berman has been granted stock options for 155,000 shares of common stock, with an exercise price of $1.91 per share and an expiration date of June 26, 2036. The options will vest on the earlier of June 26, 2027, or the day before the nex", "url": "https://www.stocktitan.net/sec-filings/IKT/form-4-inhibikase-therapeutics-inc-insider-trading-activity-2aae71f2803e.html", "source_name": "Stock Titan", "published_at": "2026-06-30T19:39:17", "published_display": "30 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibikase Therapeutics (IKT) director granted 155,000 options at $1.91 strike", "summary": "Inhibikase Therapeutics (IKT) director Vincent Aurentz was granted 155,000 stock options with an exercise price of $1.91 per share, expiring on June 26, 2036. These options will vest on the earlier of June 26, 2027, or the day before the next annual stockholder meeting, contingen", "url": "https://www.stocktitan.net/sec-filings/IKT/form-4-inhibikase-therapeutics-inc-insider-trading-activity-1381fedc12ed.html", "source_name": "Stock Titan", "published_at": "2026-06-30T19:39:17", "published_display": "30 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibikase (IKT) director receives 155,000 stock options at $1.91 strike price", "summary": "Inhibikase Therapeutics, Inc. director David Canner was granted 155,000 stock options with an exercise price of $1.91 per share, expiring on June 26, 2036. The options will vest upon his continued board service, on the earlier of June 26, 2027, or the day before the next annual s", "url": "https://www.stocktitan.net/sec-filings/IKT/form-4-inhibikase-therapeutics-inc-insider-trading-activity-95296694843f.html", "source_name": "Stock Titan", "published_at": "2026-06-30T19:39:17", "published_display": "30 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibikase (NASDAQ: IKT) investors back 3M-share plan boost and officer protections", "summary": "Inhibikase Therapeutics, Inc. stockholders approved all six management proposals at its 2026 annual meeting, including an amendment to its 2020 Equity Incentive Plan to increase shares reserved for issuance by 3,000,000 common shares. They also approved a certificate of amendment", "url": "https://www.stocktitan.net/sec-filings/IKT/8-k-inhibikase-therapeutics-inc-reports-material-event-f3f643a4b7ed.html", "source_name": "Stock Titan", "published_at": "2026-06-29T09:42:11", "published_display": "29 Jun 2026 09:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Inhibikase Therapeutics, Inc. \u2013 NASDAQ:IKT", "summary": "This article focuses on the \"Price to book forward\" metric for Inhibikase Therapeutics, Inc. (NASDAQ: IKT), indicating financial data for the company. It appears to be a financial data snippet from a larger platform rather than a detailed news analysis. The content is brief and p", "url": "https://www.tradingview.com/symbols/NASDAQ-IKT/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T03:39:38", "published_display": "29 Jun 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Inhibikase Therapeutics, Inc. \u2013 NASDAQ:IKT", "summary": "This article provides financial data for Inhibikase Therapeutics, Inc. (NASDAQ: IKT), focusing on its enterprise value to EBITDA forward metric. The information is presented by TradingView, a platform offering market data and financial analysis tools. It highlights key financial ", "url": "https://www.tradingview.com/symbols/NASDAQ-IKT/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T13:40:12", "published_display": "28 Jun 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oppenheimer Initiates Inhibikase Therapeutics at Outperform", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/oppenheimer-initiates-inhibikase-therapeutics-outperform-105359668.html", "source_name": "MT Newswires", "published_at": "2026-06-10T10:53:59+00:00", "published_display": "10 Jun 2026 10:53", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity", "summary": "", "url": "https://finance.yahoo.com/news/inhibikase-therapeutics-announces-first-quarter-200100211.html", "source_name": "GlobeNewswire", "published_at": "2026-05-12T20:01:00+00:00", "published_display": "12 May 2026 20:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Inhibikase Therapeutics (IKT) Valuation After New FDA Designations And Phase 2a Trial Progress", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-27T08:00:00+00:00", "published_display": "27 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibikase Therapeutics Announces Pricing of $110 Million", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "GlobeNewswire", "published_at": "2024-10-09T07:00:00+00:00", "published_display": "09 Oct 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inhibikase Therapeutics (IKT) Stock Price, News & Analysis $IKT", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWEFVX3lxTE13SXBYWkFQenVaU2FEYUN0R0JnRlV4MkFYXzhOcFc5SlhXMC1EMFM2YlV2MXItbzFJdmFCbUVlOVJsMVhKTmtWMDdRT0s2R0phVEd2dkFXZUw?oc=5", "source_name": "MarketBeat", "published_at": "2021-08-06T15:01:16+00:00", "published_display": "06 Aug 2021 15:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 79, "total_relevant": 40, "sentiment_summary": {"positive": 11, "negative": 3, "neutral": 26, "score": 54, "total": 40, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 10.45, "count": 19}, {"event": "earnings", "label": "Earnings", "weight": 4.81, "count": 11}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}, {"event": "deals", "label": "Deals and strategy", "weight": 1.65, "count": 3}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.65, "count": 3}], "positive_events": 11, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 2.11, "latest_week": "2026-07-17", "one_week_move": 3.4, "four_week_move": 15.3, "twelve_week_move": 12.2, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.770622, "market_dynamics_buy_signal": false, "relative_strength": 9.704553, "fair_value_gap": 14.5, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 50.0906, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+3.4% over one week, +15.3% over four weeks, trend active, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 62, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 11}, {"label": "Market source", "count": 6}, {"label": "MarketBeat", "count": 5}, {"label": "TradingView", "count": 4}, {"label": "simplywall.st", "count": 3}, {"label": "Moomoo", "count": 2}, {"label": "GlobeNewswire", "count": 2}, {"label": "MLQ.ai", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 31}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 19}, {"label": "Earnings", "count": 11}, {"label": "Analyst action", "count": 4}, {"label": "Deals and strategy", "count": 3}, {"label": "Balance sheet", "count": 3}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "31", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+3.4% over one week, +15.3% over four weeks, trend active, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Inhibikase Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition"}], "updated_at": "2026-07-22T06:02:20.184875+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}